Studies on Several Possible Antiserotonin Compounds in a Patient with the Functioning Carcinoid Syndrome
Authors: FRED Q. VROOM
Journal: Annals of Internal Medicine (1962)

Case Reports1 June 1962Studies on Several Possible Antiserotonin Compounds in a Patient with the Functioning Carcinoid SyndromeFRED Q. VROOM, M.D., RICHARD E. BROWN, M.D., HUGH DEMPSEY, M.D., S. RICHARDSON HILL JR., M.D., F.A.C.P.FRED Q. VROOM, M.D.Search for more papers by this author, RICHARD E. BROWN, M.D.Search for more papers by this author, HUGH DEMPSEY, M.D.Search for more papers by this author, S. RICHARDSON HILL JR., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-56-6-941 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn recent years, clinicians, as well as biochemists, have been intrigued by the synthesis, excretion, and metabolic effects of substances produced by neoplastic tumors, particularly tumors arising from chromaffin cells of the sympathetic nervous system.Pheochromocytomata, arising from the chromaffin tissue of the adrenal medulla and associated with disturbances in the metabolism of phenylalanine, have been widely investigated, and a relatively successful diagnostic and therapeutic approach now has been delineated for these tumors. Less well understood and of considerable current clinical interest are the chromaffin cell neoplasms of the gastrointestinal tract (1), designated as malignant carcinoid tumors. An abnormality of...References1. COPLAND SM: Carcinoid disease. Dis. Colon Rectum 1: 471, 1958. CrossrefMedlineGoogle Scholar2. THORSONBIÖRCKBJÖRKMANWALDENSTRÖM AGGJ: Malignant carcinoid of small intestine with metastases to liver, valvular disease of right side of heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and unusual type of cyanosis; clinical and pathological syndrome. Amer. Heart J. 47: 795, 1954. CrossrefMedlineGoogle Scholar3. SJOERDSMA A: Clinical and laboratory features of malignant carcinoid. Arch. Intern. Med. 102: 936, 1958. CrossrefGoogle Scholar4. SJOERDSMA A: Serotonin. New Engl. J. Med. 261: 181, 231, 1959. CrossrefMedlineGoogle Scholar5. WEISSBACHLOVENBERGREDFIELDUDENFRIEND HWBGS: In vivo metabolism of serotonin and tryptamine: effect of monoamine oxidase inhibition. J. Pharmacol. Exp. Ther. 131: 26, 1961. MedlineGoogle Scholar6. PAGE IH: Serotonin (5-hydroxytryptamine); the last four years Physiol. Rev. 38: 277, 1958. CrossrefMedlineGoogle Scholar7. AUSTERNJOHANSSONLUNDBERGSJÖBERG HSAH: Heparin treatment in a case of carcinoid tumour. Acta Med. Scand. 168: 367, 1960. CrossrefMedlineGoogle Scholar8. SJOERDSMAOATESZALTMANUDENFRIEND AJAPS: Serotonin synthesis in carcinoid patients. (Its inhibition by alpha-methyl-dopa with measurement of associated increases in urinary 5-hydroxytryptophan.) New Engl. J. Med. 263: 585, 1960. CrossrefMedlineGoogle Scholar9. COLLINI FJ: Use of alpha-methyl-dopa (alpha-methyl-3,4-dihydroxy-dl-phenylalanine) in the management of the carcinoid syndrome. New Engl. J. Med. 264: 986, 1961. CrossrefMedlineGoogle Scholar10. BENDITTROWLEY EPDA: Antagonism of 5-hydroxytryptamine by chlorpromazine. Science 123: 24, 1956. CrossrefMedlineGoogle Scholar11. KABABOWWEINSTEINROSSTRESSER BIBGM: A clinical and metabolic study of metastatic carcinoid. Amer. J. Med. 26: 636, 1959. CrossrefMedlineGoogle Scholar12. BEANFUNK WBD: The vasculocardiac syndrome of metastatic carcinoid. Arch. Intern. Med. 103: 189, 1959. CrossrefGoogle Scholar13. STONEWENGERLUDDENSTAVORSKIROSS CAHCCTJMCA: Antiserotonin-antihistaminic properties of cyproheptadine. J. Pharmacol. Exp. Ther. 131: 73, 1961. Google Scholar14. DAVISROSENBERG RBJC: Carcinoid syndrome associated with hyperserotoninemia and normal 5-hydroxyindoleacetic acid excretion. Amer. J. Med. 30: 167, 1961. CrossrefMedlineGoogle Scholar15. UDENFRIENDTITUSWEISSBACH SEH: Identification of 5-hydroxy-3-indoleacetic acid in normal urine and method for its assay. J. Biol. Chem. 216: 499, 1955. CrossrefMedlineGoogle Scholar16. CLARKTHOMPSON LCHL: Determination of creatine and creatinine in urine. Anal. Chem. 21: 1218, 1949. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: FRED Q. VROOM, M.D.; RICHARD E. BROWN, M.D.; HUGH DEMPSEY, M.D.; S. RICHARDSON HILLJR., M.D., F.A.C.P.Affiliations: Birmingham, AlabamaFrom the Division of Metabolism and Endocrinology, the Department of Medicine and University Hospital, University of Alabama Medical Center, and the Medical Service, Veterans Administration Hospital, Birmingham, Alabama.This study was aided in part by Grants 2A-5053, A-3555, and Cy-5301 from the National Institute of Arthritis and Metabolic Diseases and the National Cancer Institute of the National Institutes of Health, Bethesda, Maryland, and by funds from the Upjohn Company, Kalamazoo, Michigan, the Eli Lilly Company, Indianapolis, Indiana, and Wyeth Laboratories, Philadelphia, Pennsylvania.Requests for reprints should be addressed to S. Richardson Hill, Jr., M.D., Department of Medicine, The University of Alabama Medical Center, Birmingham 3, Alabama. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCarcinoid SyndromeCarcinoid SyndromeA Case of Malignant Endocrine Tumor of the Stomach that Responded to ChemotherapyCarcinoid Syndrome and Disorders of Systemic Mast-Cell Activation Including Systemic MastocytosisCarcinoid syndrome and intravenous cyproheptadineTherapy of Metastatic Carcinoid Tumor and the Carcinoid SyndromeChemotherapy for the carcinoid syndromeAbsorption, Distribution, Metabolism, and Elimination of AntihistaminesCarcinoid syndrome: its relevance to the anaesthetistAnaesthesia for a patient with carcinoid syndromeCarcinoid myopathy and treatment with cyproheptadine (Periactin)Chemotherapeutic management of the hormone-secreting endocrine malignanciesSerotonin Now: Clinical Implications of Inhibiting Its Synthesis with Para-ChlorophenylalanineALBERT SJOERDSMA, M.D., Ph.D., WALTER LOVENBERG, Ph.D., KARL ENGELMAN, M.D., WILLIAM T. CARPENTER JR., M.D., RICHARD J. WYATT, M.D., GIAN L. GESSA, M.D.Carcinoid — its TreatmentTreatment of Gastrointestinal Cancer: Current Status and Recent ProgressGastrointestinal Carcinoids and the Carcinoid Syndrome: Clinical Characteristics and TherapyPhenothiazinesTherapy of the Malignant Carcinoid SyndromeCHARLES E. MENGEL, M.D.Clinical and biochemical effects of cyclophosphamide in patients with malignant carcinoidTreatment of Malabsorption and Diarrhea of the Carcinoid Syndrome with MethysergideTreatment of Disseminated Carcinoid Tumors Including Hepatic-Artery CatheterizationThe endocrinologic effects of tumors 1 June 1962Volume 56, Issue 6Page: 941-945KeywordsCellsEndocrinologyExcretionHospital medicineMedical servicesMetabolic disordersPhenylalanineResearch laboratoriesSerotoninSympathetic nervous system ePublished: 1 December 2008 Issue Published: 1 June 1962 PDF downloadLoading ...